Bio Rad Laboratories Stock Investor Sentiment

BIO Stock  USD 254.17  5.86  2.25%   
About 64% of Bio Rad's investor base is looking to short. The analysis of overall sentiment of trading Bio Rad Laboratories stock suggests that many investors are alarmed at this time. Bio Rad's investing sentiment overview a quick insight into current market opportunities from investing in Bio Rad Laboratories. Many technical investors use Bio Rad Laboratories stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

Comfort Level 36

 Alarmed

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Bio Rad's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Bio Rad Laboratories.

Bio Historical Sentiment

Although Bio Rad's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Bio, such as negative comments on social media and news outlets, may cause fear in the market and push Bio Rad's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Bio.
  

Bio Rad Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Bio Rad can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Bio Rad Laboratories Historical Investor Sentiment

Investor biases related to Bio Rad's public news can be used to forecast risks associated with an investment in Bio. The trend in average sentiment can be used to explain how an investor holding Bio can time the market purely based on public headlines and social activities around Bio Rad Laboratories. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Bio Rad's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bio Rad and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Bio Rad news discussions. The higher the estimate score, the more favorable the investor's outlook on Bio Rad.

Bio Rad Maximum Pain Price Across June 20th 2025 Option Contracts

Bio Rad's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Bio Rad close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Bio Rad's options.
a minute ago at kalkinemedia.com         
Microplate Systems Market Size to Worth 1336.79 USD million by 2030 With a 4.85 percent CAGR by Exac...
news
2 days ago at simplywall.st         
Does Bio-Rad Laboratories Have A Healthy Balance Sheet?
Simply Wall St News at Macroaxis
3 days ago at thelincolnianonline.com         
one8zero8 LLC Acquires Shares of 674 Bio-Rad Laboratories, Inc.
news
few days ago at www.macroaxis.com         
Disposition of tradable shares by Allison Schwartz of Bio Rad at 4.6 subject to Rule 16b-3
Macroaxis News
few days ago at thelincolnianonline.com         
Bio-Rad Laboratories, Inc. Shares Sold by PNC Financial Services Group Inc.
news
six days ago at globenewswire.com         
Cell Signaling Market Analysis Report 2025 Global Industry Size, Share, Trends, Opportunities and Fo...
Macroaxis News: globenewswire.com
over a week ago at businesswire.com         
MTF Biologics Expands Partnership with Kolosis BIO to Strengthen DBX Brand
businesswire News
over a week ago at globenewswire.com         
Neurological Biomarkers Global Market Review 2020-2024 and Forecast to 2030, Featuring Analysis of P...
Macroaxis News: globenewswire.com
over a week ago at businessnewsaustralia.com         
Australias Top 100 Young Entrepreneurs 11-20
news
over a week ago at kalkinemedia.com         
Proteomics Market Projected To Witness Substantial Growth, 2025-2032 Bio-Rad Laboratories, Inc., GE ...
news
over a week ago at news.google.com         
Bio-Rad stock touches 52-week low at 248.05 amid market shifts - Investing.com India
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Biome Australia Limited Insider Geoffrey Sam Acquires 43,240 Shares
news
over a week ago at globenewswire.com         
Japan In-Vitro Diagnostics Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, D...
Macroaxis News: globenewswire.com
over a week ago at finance.yahoo.com         
Microplates Market to Reach USD 1,301.08 million by 2032, Growing at an 4.50 percent CAGR - Credence...
Yahoo News
over two weeks ago at finance.yahoo.com         
Is Bio-Rad Laboratories, Inc. the Best Medical Technology Stock to Buy According to Analysts?
Yahoo News
Far too much social signal, news, headlines, and media speculation about Bio Rad that are available to investors today. That information is available publicly through Bio media outlets and privately through word of mouth or via Bio internal channels. However, regardless of the origin, that massive amount of Bio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bio Rad news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bio Rad relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bio Rad's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bio Rad alpha.

Bio Rad Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Biochips Market Expected To Reach USD 67.67 Billion by 2032, with a CAGR of 21.10 percent PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories
01/23/2025
2
Earnings Preview Bio-Rad Laboratories Q4 Earnings Expected to Decline
02/06/2025
3
Disposition of 298 shares by Michael Crowley of Bio Rad at 4.6 subject to Rule 16b-3
02/14/2025
4
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of blue...
02/25/2025
5
21 Billion Microfluidic Device Systems Market Analysis 2030 Tripling in Size from 2024
02/27/2025
6
Staar Surgical, BD, Acutus Medical announce layoffs in Southern California
02/28/2025
7
Fisher Asset Management LLC Grows Stock Holdings in Bio-Rad Laboratories, Inc.
03/03/2025
8
Bio-Rad Laboratories Inc Trading 3.6 percent Higher on Mar 5
03/05/2025
9
Japan In-Vitro Diagnostics Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, Danaher, Biomerieux, Roche, Becton, Sysmex, Bio-Rad Laborator...
03/07/2025
10
Proteomics Market Projected To Witness Substantial Growth, 2025-2032 Bio-Rad Laboratories, Inc., GE Healthcare, Bruker
03/10/2025
11
MTF Biologics Expands Partnership with Kolosis BIO to Strengthen DBX Brand
03/12/2025
12
Disposition of tradable shares by Allison Schwartz of Bio Rad at 4.6 subject to Rule 16b-3
03/14/2025
When determining whether Bio Rad Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Rad's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Rad Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Rad Laboratories Stock:
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
5.412
Earnings Share
(65.36)
Revenue Per Share
90.965
Quarterly Revenue Growth
(0.02)
Return On Assets
0.0155
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.